Fig. 2: Senolytic responses of A549 TIS cancer cells to BH3 mimetics.
From: Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies
A549 lung cancer cells were treated with senescence-inducing concentrations of bleomycin, alisertib, doxorubicin, or palbociclib for 7 days. Senescent cells and proliferative (untreated) cells were replated in 12-well plates (100,000 cells/well and 50,000 cells/well, respectively) and cultured with increasing concentrations of ABT-263/navitoclax, A13318512, ABT-199/venetoclax, or S63845. After 5 days, cell growth and senescence were monitored by crystal violet staining (left panels) and SA-β-gal staining (right panels). Shown are representative images from three technical replicates. Scale bar = 200 μm. Bottom left. BH3 mimetic/anti-apoptotic protein interaction pattern and senolytic sensitivity profile of TIS phenotypes. ABT-263/navitoclax inhibits BCL-2 and BCL-XL, A13318512 inhibits BCL-XL only, ABT-199/venetoclax inhibits BCL-2 only, and S63845 inhibits MCL1 only. Bottom right. Summary of the responses of A549 TIS cancer cells to BH3 mimetics.
